إسرائيل - العبرية - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - lactic acid as sodium 3.925 g/l; calcium chloride 0.2573 g/l; glucose as monohydrate 46.75 g/l; magnesium chloride 0.1017 g/l; sodium chloride 5.786 g/l - combinations of electrolytes - combinations of electrolytes - for patients with (decompensated) chronic renal failure being maintained on peritoneal dialysis.

إسرائيل - العبرية - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - calcium chloride 0.2573 g/l; sodium chloride 5.786 g/l; glucose as monohydrate 25 g/l; lactic acid as sodium 3.925 g/l; magnesium chloride 0.1017 g/l - combinations of electrolytes - combinations of electrolytes - for patients with (decompensated ) chronic renal failure being maintained on peritoneal dialysis.

إسرائيل - العبرية - Ministry of Health

glaxo smith kline (israel) ltd - mupirocin - משחה - mupirocin 2 %w/w - mupirocin - mupirocin - acute primary bacterial skin infections susceptible to the drug e.g. impetigo and folliculitis.

إسرائيل - العبرية - Ministry of Health

teva israel ltd - mupirocin - משחה - mupirocin 2 % - mupirocin - mupirocin - acute primary bacterial skin infections susceptible to the drug e.g. impetigo and folliculitis.

إسرائيل - العبرية - Ministry of Health

j-c health care ltd - oxybutynin chloride - טבליות בשחרור ממושך - oxybutynin chloride 5 mg - oxybutynin - oxybutynin - once daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

إسرائيل - العبرية - Ministry of Health

j-c health care ltd - oxybutynin chloride - טבליות בשחרור ממושך - oxybutynin chloride 10 mg - oxybutynin - oxybutynin - once daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

إسرائيل - العبرية - Ministry of Health

taro pharmaceutical industries ltd - triamcinolone - טבליה - triamcinolone 4 mg - triamcinolone - triamcinolone - releif of inflamed areas of the body, reduces swelling, redness, itching and allergic reactions.

إسرائيل - العبرية - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

إسرائيل - العبرية - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

إسرائيل - العبرية - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.